By Maksym Misichenko · Yahoo Finance ·
What AI agents think about this news
The panel consensus is that Amgen's (AMGN) stock faces significant near-term risks, primarily the IRS tax dispute and the upcoming MariTide clinical readout, outweighing the potential benefits from Repatha's CV data and Imdylltra's approval. The panelists generally agree that the stock's upside may be capped due to these risks.
Risk: The IRS tax dispute and the MariTide clinical readout are the single biggest risks flagged by the panelists.
Opportunity: The expansion of Repatha's addressable market due to its CV risk reduction data is the single biggest opportunity flagged.
This analysis is generated by the StockScreener pipeline — four leading LLMs (Claude, GPT, Gemini, Grok) receive identical prompts with built-in anti-hallucination guards. Read methodology →
Amgen Inc. (NASDAQ:AMGN) is one of the
7 Best Longevity Stocks to Buy Now.
On June 7, 2026, Amgen Inc. (NASDAQ:AMGN) announced new data at the American Diabetes Association 86th Scientific Sessions, including Phase 3 VESALIUS-CV subgroup results for Repatha in patients with high-risk diabetes and elevated LDL-C without prior heart attack or stroke. In an analysis of 6,002 patients, Repatha, when added to statins or other LDL-C-lowering therapies, reduced the risk of the composite primary endpoint of coronary heart disease death, myocardial infarction, or ischemic stroke by 29% compared with placebo. Repatha also reduced the risk of a second composite primary endpoint that included ischemia-driven revascularization by 21%.
On June 5, 2026, Goldman Sachs lowered the firm’s price target on Amgen Inc. (NASDAQ:AMGN) to $389 from $425 and maintained a Buy rating on the shares. Goldman Sachs adjusted its model after Amgen disclosed in its Q1 earnings that the IRS audit for 2016 to 2018 had escalated into a formal dispute, with the company receiving a notice of proposed adjustment.
Earlier in June, Amgen announced that the European Commission granted marketing authorization for Imdylltra as a monotherapy for adults with extensive-stage small cell lung cancer who require systemic therapy after disease progression on or after first-line platinum-based chemotherapy.
Amgen Inc. (NASDAQ:AMGN) discovers, develops, manufactures, and delivers human therapeutics worldwide.
While we acknowledge the potential of AMGN as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.
READ NEXT: 33 Stocks That Should Double in 3 Years and Cathie Wood 2026 Portfolio: 10 Best Stocks to Buy.** **
Disclosure: None. Follow Insider Monkey on Google News.
Four leading AI models discuss this article
"The escalating IRS audit creates a tax overhang that the article’s clinical headlines do not adequately address."
The article positions AMGN as a longevity play on Repatha’s 29% risk reduction in high-risk diabetes patients and Imdylltra’s EU approval for small-cell lung cancer. Yet it underplays Goldman Sachs cutting the price target to $389 after the IRS escalated a 2016-2018 audit into a formal dispute with a proposed adjustment. That tax exposure could hit cash flows and valuation at a time when the piece itself pivots readers toward AI names instead. Longevity narratives often ignore near-term balance-sheet risks that clinical wins alone cannot offset.
The IRS matter could settle for far less than feared given Amgen’s history of resolving audits without material hits, leaving the new cardiovascular and oncology data to re-rate shares higher.
"The touted benefits hinge on subgroup CV data with uncertain durability, and near-term tax/payer headwinds could cap upside, making the risk/reward skew bearish."
Article ties AMGN to longevity catalysts—Repatha CV data and Imdylltra approval—to push a Buy case. But the Repatha result is a subgroup analysis with a 6,002-patient sample; without broader CV outcomes or solid absolute risk reduction metrics, the durability of the signal is uncertain. The Imdylltra label expansion is modest and faces competition, payer hurdles, and end-market constraints. The Goldman cut and the IRS dispute add near-term headline risk. The stock may already reflect some of these catalysts, and downstream monetization (pricing power, uptake) hinges on payer dynamics and pipeline success, not a single data readout. Upside may be capped vs. risk.
Even if subgroup results look promising, the lack of universal CV outcomes and real-world uptake means the market could sour. The IRS dispute could escalate into meaningful tax penalties, creating outsized downside risk in the near term.
"Amgen's strong clinical pipeline is currently being neutralized by the overhang of a significant, unresolved IRS tax dispute."
Amgen’s clinical data for Repatha is compelling, but the market is clearly prioritizing the IRS tax dispute over incremental pipeline wins. The 29% risk reduction in high-risk diabetes patients is a massive TAM (Total Addressable Market) expansion, yet the Goldman Sachs price target cut to $389 signals that institutional investors are pricing in a significant tax liability overhang. At current levels, AMGN is trading at roughly 14x forward earnings, which is reasonable for a blue-chip biotech, but the tax litigation creates a 'dead money' scenario until the settlement figure is finalized. I view the clinical success as a floor for the stock, while the tax risk acts as a ceiling.
The IRS dispute could result in a multi-billion dollar settlement that forces Amgen to cut R&D spending or dividend growth, effectively neutralizing the long-term value of their recent clinical breakthroughs.
"The IRS audit escalation represents unquantified tail risk that likely outweighs near-term Repatha upside, and Goldman's 8.5% downgrade suggests the market hasn't fully priced this in."
AMGN's Repatha data is genuinely meaningful—29% CV risk reduction in high-risk diabetics expands addressable market beyond prior indications. But the article buries the lede: Goldman downgraded price target $36 (8.5%) on an IRS audit escalation into formal dispute for 2016–2018 tax years. That's material tax liability risk the longevity framing obscures. Imdylltra approval is incremental. The real question: what's the IRS exposure? If it's $500M+, the $389 target implies GS sees downside even with Repatha upside priced in.
If the IRS dispute resolves favorably or settles for a manageable amount, AMGN's pipeline strength (Repatha expansion, Imdylltra, MariTide) could drive re-rating back to $425+ within 18 months, making the dip a buying opportunity.
"Amgen's audit history suggests limited tax impact, allowing clinical data to drive value despite the overhang."
Gemini frames the tax dispute as a hard ceiling on valuation, yet overlooks how Amgen's prior audit resolutions averaged under 20% of proposed adjustments. At 14x forward earnings, any settlement below $1B would likely be absorbed without cutting R&D, letting the diabetes subgroup data still expand Repatha scripts. The real unpriced risk is whether payers demand deeper discounts on the new indication.
"The IRS dispute is a meaningful near-term risk that should be modeled as a downside range, not dismissed as a small, historical average adjustment."
Grok minimizes the IRS dispute by citing historical audit resolutions as typically small. That logic presumes uniform outcomes across years and tax law. In this cycle, a formal dispute elevates risk of penalties and interest, and even a moderate settlement could meaningfully compress near-term cash flow, potentially delaying buybacks or R&D spend. Treat the IRS exposure as a range with downside risk, not a binary 'settles small' outcome.
"The market is ignoring the existential risk of the MariTide pipeline in favor of debating manageable tax litigation."
Gemini and Grok are fixated on the tax dispute as a binary event, but both ignore the real structural headwind: MariTide. The market is pricing AMGN as a legacy biotech, yet the entire valuation thesis now hinges on the obesity pipeline. If MariTide data shows even slight bone density concerns, the stock craters regardless of the IRS settlement. We are debating tax accounting while the company’s future is being determined by a single, high-stakes clinical readout.
"MariTide execution risk is real, but IRS settlement timing and magnitude directly constrain the R&D firepower Amgen needs to defend obesity market share against Novo/Eli Lilly."
Gemini's MariTide pivot is sharp—obesity pipeline risk dwarfs tax dispute noise. But conflating 'legacy biotech' with 'tax dispute irrelevance' is wrong. A $1.5B+ IRS settlement forces real capex trade-offs that compress R&D velocity precisely when MariTide phase 3 readouts matter most. Tax drag + clinical miss = compounding downside, not independent risks.
The panel consensus is that Amgen's (AMGN) stock faces significant near-term risks, primarily the IRS tax dispute and the upcoming MariTide clinical readout, outweighing the potential benefits from Repatha's CV data and Imdylltra's approval. The panelists generally agree that the stock's upside may be capped due to these risks.
The expansion of Repatha's addressable market due to its CV risk reduction data is the single biggest opportunity flagged.
The IRS tax dispute and the MariTide clinical readout are the single biggest risks flagged by the panelists.